improving the half-life and efficacy of ADCs through strategies like the use of albumin-binding domains or small-format antibodies is an area of active research. Design principles for bispecific ...

The debate between CAR T-cell therapy and bispecific antibodies is not a rivalry but a question of sequencing, ...

At EHA 2025, the preliminary results from the global, multi-centre open-label non-randomised Phase II RedirecTT-1 clinical ...

Learn how antibody to payload design is crucial for advancing ADC technology in oncology and beyond with expert insights.

At ASCO 2025, an expert discusses encouraging new early-phase research in clinical trials on treating myeloma.

Veraxa Biotech has entered a joint discovery partnership with OmniAb tp develop a bispecific antibody drug conjugate ... in Veraxa’s pipeline growth strategy, and today’s announcement marks ...

Bispecific antibodies (bsAbs) are shaping the future of therapeutics, but challenges like limited throughput, low yields, and chain mispairing across diverse formats can slow progress. This white ...

This progress has accelerated our ability to design and develop innovative ... including multiple globally first-in-class bispecific antibodies, multi-specific antibodies, and antibody-drug ...

The granted claims cover the novel design and therapeutic applications of bispecific antibodies that simultaneously ... milestone in our global expansion strategy,” said Chirinjeev Kathuria ...

and the development of the clinical trial design. Merus N.V. is sponsoring the ongoing study, which continues to recruit patients worldwide. Zenocutuzumab is a first-in-class, humanized, full-length ...

BioNTech agreed to buy CureVac for $1.25 billion, expanding its mRNA cancer research and boosting its oncology pipeline.